FIGURE LEGENDS
FIGURE 1. A) Levels of HCMV DNA in whole blood (WB DNAemia), HCMV DNA in plasma (PL DNAemia) and PL UL21.5 mRNA in episodes of clinically significant DNAemia (requiring pre-emptive therapy) or transient self-resolving DNAemia. B) Median kinetics of WB DNAemia, PL DNAemia and PL UL21.5 mRNA. Data were normalized by considering 100% the peak value of viral load detected by different assays the day of starting therapy (day 0) and then referring to it as percentages all values detected by the relevant assay either prior to or after onset of therapy. C) Clearance of WB DNAemia, PL DNAemia and PL UL21.5 mRNA after treatment.
FIGURE 2. A) Levels of human Rhinovirus (HRV) RNA; B) levels of UL21.5 mRNA in purified preparations of AD169 and VR1814 strains; and C) levels of UL21.5 mRNA in plasma, before or after ribonuclease (RNAse) treatment.
FIGURE 3. Pearson’s correlation between UL21.5 mRNA in plasma and A) whole blood (WB) DNAemia; B) plasma (PL) DNAemia; C) PL DNAemia after DNAse treatment (i.e. virion-associated PL DNAemia); and C) number of leukocytes carrying infectious virus.
FIGURE 4. Levels of A) whole blood (WB) DNAemia or B) plasma (PL) DNAemia in samples positive or negative for UL21.5 mRNA.
FIGURE 5. Levels of HCMV DNA in whole blood (WB DNAemia) and plasma (PL) UL21.5 mRNA in episodes of DNAemia associated with resistance to letermovir (LTV) or maribavir (MBV) or in episodes of transient self-resolving DNAemia blips in the absence of resistance to antiviral drugs.